In ADC design, the payload–linker is the functional module that governs how a small molecule is attached, carried, and released by an antibody. We design, manufacture, and qualify payload–linker constructs across cleavable and non-cleavable families—paired with practical handles (e.g., maleimide, NHS ester, azide/DBCO, TCO/tetrazine)—to support diverse conjugation strategies and site-selection approaches. Our focus is on consistent quality, scalable synthesis, and analytical traceability so teams can advance ADC efficiently in laboratory settings.
Overview of Payload-Linkers
Payload–linkers are the engineered bridges that couple cytotoxic payloads to antibodies and control when, where, and how drug is released. Designs fall into cleavable (enzymatic, reductive, or acid-labile; often with self-immolative spacers like PABC) and non-cleavable types that require complete antibody degradation. Key parameters—plasma stability, release kinetics, hydrophilicity, and conjugation chemistry—govern efficacy, bystander effect, and safety. Modern linkers incorporate polarity boosters (e.g., PEG/polysarcosine) to reduce aggregation at higher DARs and use site-specific handles (engineered cysteines, enzymatic tags, click reagents) for uniform products. Selecting and optimizing the payload–linker pair is central to maximizing tumor selectivity while minimizing systemic toxicity in antibody–drug conjugates (ADCs).
Fig.1 Schematic diagram of commonly used antibody drug-conjugate. (Kondrashov, et al., 2023)
Roles of Payload-Linkers in ADC
Payload–linker as the operational core of an ADC: it governs release timing and catabolite identity, shapes DAR and product heterogeneity during conjugation, and tunes the biophysical profile that drives purification and assay performance. By aligning handle chemistry with the intended conjugation site—and enabling orthogonal or dual designs when required—the payload–linker becomes the practical lever that connects molecular design with reliable, measurable outcomes in discovery and process development.
- Define release mechanics and catabolite identity: The payload–linker determines when and how the payload is liberated, as well as the structure of measurable catabolites for mass-spectrometric monitoring.
- Control DAR and heterogeneity: Built-in handles and linker architecture support desired drug-to-antibody ratio targets and reduce by-product formation during conjugation.
- Tune biophysical properties: Spacer length, charge, and masking elements within the payload–linker modulate ADC hydrophobicity and aggregation behavior for bench-scale purification and analytics.
- Enable site strategy: Compatibility with cysteine, lysine, engineered amino acids, or enzymatic tags allows alignment with the chosen site-specificity scheme.
- Support dual/orthogonal designs when needed: Distinct trigger chemistries and handles can enable multi-payload concepts while maintaining separation of conjugation pathways.
- Accelerate analytics: Signature fragments embedded in the payload–linker (e.g., cleavable markers or stable surrogates) facilitate LC–MS, HIC, and peptide-mapping workflows.
Advantages of Our Payload-Linker Products
Payload–linker portfolio is built for laboratory teams that need predictable activation modes, clean conjugation, and straightforward analytics. We supply ready-to-use constructs spanning complementary trigger chemistries and handles, with spacers and solubilizing features tuned for developability. Coupled with reference data and options for customization, these materials provide a clear path from concept to well-characterized ADC constructs in research workflows.
- Proprietary Linker Chemistries: Customizable cleavage triggers (pH, enzymes, redox) for tailored release profiles.
- Enhanced Stability: Advanced PEGylation and hydrophobicity-masking techniques reduce aggregation and extend half-life.
- Comprehensive Support: From linker-payload design to analytical validation, we partner with clients to accelerate therapeutic development.
Frequently Asked Questions
Q1: How do I select the optimal payload–linker for my antibody?
Choose based on the antibody's internalization behavior, the desired activation trigger (enzyme, redox, pH, or non-cleavable), and the payload's physicochemical profile. We map these factors to scaffold families and handles that support your target DAR and conjugation route.
Q2: Will the payload–linker stay intact until the intended trigger is encountered?
Payload–linker constructs are designed for stability under standard storage and plasma-mimicking conditions used in laboratory evaluations, while providing responsive activation under the specified trigger to yield the expected catabolites.
Reference
- Kondrashov, A.; et al. Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload. 2023, Pharmaceutics, 15(8), 2160.